"Pertussis Vaccine" in Patent Application Approval Process (USPTO 20240181030).

ModernaTX Inc. has filed a patent application for a ribonucleic acid (RNA) vaccine that targets whooping cough, diphtheria, and tetanus. The vaccine uses messenger RNA (mRNA) to instruct the body to produce specific proteins that can fight these diseases. The vaccine contains multiple mRNA polynucleotides that encode various antigenic polypeptides for Bordetella pertussis. It has the potential to treat and prevent infections caused by different strains and genotypes of these diseases. The patent application includes claims for different compositions of the vaccine, as well as specific amino acid and nucleotide sequences for the antigenic polypeptides. [Extracted from the article]